5‐FU/cisplatin/anthracycline combinations may leads to lower overall survival compared with 5‐FU/anthracycline combinations (without cisplatin) (low certainty).
5‐FU/cisplatin/anthracycline combinations probably leads to lower overall survival compared with 5‐FU/cisplatin combinations (without anthracyclines) (moderate certainty).
5‐FU/cisplatin/anthracycline combinations may leads to higher tumour response compared with 5‐FU/cisplatin combinations (without anthracyclines) (low certainty).
5‐FU/cisplatin/anthracycline combinations may leads to lower time to progression compared with 5‐FU/cisplatin combinations (without anthracyclines) (low certainty).
Gemcitabine combinations showed no clear difference in overall survival ‐ Gemcitabine plus topoisomerase inhibitor compared with gemcitabine alone (high certainty).
Gemcitabine combinations leads to lower overall survival ‐ Gemcitabine plus taxane compared with gemcitabine alone (high certainty).
Gemcitabine combinations showed no clear difference in overall survival ‐ Gemcitabine plus other agent(s) compared with gemcitabine alone (low certainty).
Gemcitabine combinations showed no clear difference in overall survival ‐ Gemcitabine plus platinum agent compared with gemcitabine alone (low certainty).
Gemcitabine combinations leads to lower overall survival ‐ Gemcitabine plus fluoropyrimidine compared with gemcitabine alone (high certainty).
Fluoropyrimidine combinations showed no clear difference in overall survival compared with fluoropyrimidine alone (low certainty).
It is very uncertain whether taxane‐platinum‐fluoropyrimidine combinations changes overall survival compared with taxane‐platinum (without fluoropyrimidine) (very low certainty).
Taxane‐platinum‐fluoropyrimidine combinations may leads to higher tumour response compared with taxane‐platinum (without fluoropyrimidine) (low certainty).
Taxane‐platinum‐fluoropyrimidine combinations probably leads to lower progression‐free survival compared with taxane‐platinum (without fluoropyrimidine) (moderate certainty).
It is very uncertain whether taxane‐platinum‐fluoropyrimidine combinations changes treatment‐related death compared with taxane‐platinum (without fluoropyrimidine) (very low certainty).
It is very uncertain whether taxane‐platinum‐fluoropyrimidine combinations changes treatment discontinuation due to toxicity compared with taxane‐platinum (without fluoropyrimidine) (very low certainty).
Carboplatin showed no clear difference in overall survival (baseline risks for low‐ and high‐risk groups in… compared with cisplatin chemotherapy (high certainty).
Carboplatin showed no clear difference in 1‐year survival rate compared with cisplatin chemotherapy (high certainty).
Carboplatin showed no clear difference in response rate compared with cisplatin chemotherapy (high certainty).
Carboplatin probably leads to higher grade III or IV neurotoxicity compared with cisplatin chemotherapy (moderate certainty).
Carboplatin probably leads to higher grade III or IV thrombocytopenia compared with cisplatin chemotherapy (moderate certainty).